94.07MMarket Cap-1211P/E (TTM)
1.340High1.300Low431.61KVolume1.310Open1.310Pre Close568.10KTurnover0.77%Turnover RatioLossP/E (Static)71.26MShares10.71552wk High0.66P/B73.90MFloat Cap0.59052wk Low--Dividend TTM55.99MShs Float33.880Historical High--Div YieldTTM3.05%Amplitude0.590Historical Low1.316Avg Price1Lot Size
Aclaris Therapeutics Stock Forum
On July 19, 2024, Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, announced the sale of a portion of its future royalty payments and certain milestones related to OLUMIANT® (baricitinib) to OMERS...
Aclaris Therapeutics Shares Are Trading Higher After the Company Announced the Sale of OLUMIANT Royalties and Milestones to OMERS Life Sciences for up to $31.5 Million
Aclaris Therapeutics Inc - Receives $26.5M Upfront Payment
Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
Aclaris Therapeutics (NASDAQ: ACRS) has announced the sale of a portion of its future royalty payments and certain milestones for OLUMIANT® (baricitinib) to OMERS Life Sciences for up to $31.5 million. The deal includes a $26.5 million upfront payment and up to $5.0 million in potential milestone payments based on OLUMIANT sales in 2024. Thi...
No comment yet